Seelos Therapeutics, Inc. (SEEL)

NASDAQ: SEEL · IEX Real-Time Price · USD
0.639
+0.112 (21.19%)
At close: Mar 27, 2024, 4:00 PM
0.621
-0.019 (-2.94%)
After-hours: Mar 27, 2024, 7:47 PM EDT

Company Description

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders.

The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD).

Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012.

The company was founded in 2016 and is headquartered in New York, New York.

Seelos Therapeutics, Inc.
Seelos Therapeutics logo
Country United States
Founded 2016
Industry Biotechnology
Sector Healthcare
Employees 15
CEO Dr. Raj Mehra J.D., Ph.D.

Contact Details

Address:
300 Park Avenue, 2nd Floor
New York, New York 10022
United States
Phone (646) 293-2100
Website seelostherapeutics.com

Stock Details

Ticker Symbol SEEL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001017491
CUSIP Number 81577F109
ISIN Number US81577F2083
Employer ID 87-0449967
SIC Code 2834

Key Executives

Name Position
Dr. Raj Mehra J.D., Ph.D. Founder, Chairman, Chief Executive Officer and President
Michael J. Golembiewski Chief Financial Officer
Kimberly Farrand Senior Director of Clinical Development and Operations
Anthony Marciano Chief Communications Officer
Gopal Krishna Ph.D. Head of Manufacturing and Technical Operations
Tim Whitaker M.D. Chief Medical Officer
Karen Fusaro Senior Vice President and Head of Clinical Operations

Latest SEC Filings

Date Type Title
Mar 19, 2024 8-K Current Report
Mar 15, 2024 EFFECT Notice of Effectiveness
Mar 15, 2024 424B3 Prospectus
Mar 7, 2024 S-8 Securities to be offered to employees in employee benefit plans
Mar 6, 2024 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Mar 6, 2024 10-K Annual Report
Feb 14, 2024 D Notice of Exempt Offering of Securities
Feb 6, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 2, 2024 S-1 General form for registration of securities under the Securities Act of 1933
Jan 30, 2024 8-K Current Report